Here is why there will be little impact, even if many more manufacturers agree to negotiate. Most patients will not see an impact from the price concessions since these agreements are for Medicaid patients and patients without insurance. Medicaid patients comprise around 24% of the US population and the uninsured comprise around 9%. These two deals do not impact the two largest healthcare populations in the US: insured and Medicare patients.

Trump RX has great potential, but without putting other guardrails in place it will be another windfall for middlemen in the drug supply chain.